The lake is not as shallow as it seems

Abstract

In the last two years the world has experienced a health crisis with the coronavirus 19 (COVID-19) pandemic. The exponential growth of new cases of the disease in the world and the increase in morbidity and mortality led to the incessant search for new therapies that could increase the cure of the infection. One of these new therapeutic possibilities was the ivermectiva, which in Salvador -Bahia, an exponential growth in consumption was observed in the years 2020 and 2021, reaching a 987.7% increase and an estimated expense of R$ 12 million . When checking the Pharmacovigilance data obtained from the VIGIMED portal, in 2020, 11 adverse reactions associated with IVR were reported, and in 2021, 21 ADRs. The underreporting rate of adverse drug reactions (ADRs) for spontaneous reporting systems a median of underreporting of 94% can be verified. The data available in the ANVISA databases should be carefully considered, in order to establish information on safety in the use of medicines.